Q1FY22 Earnings Presentation

8 Strides 4 Financial performance in Q1FY22 Q1FY22 Q4FY21 Q1FY21 QoQ% YOY% Revenues *6,919m *9,115m *7,847m - 24% -12% Gross Margins *3,428m *5,400m *4,825m - 37% 49.5% 59.2% 61.5% - 970bps - 29% -1,200 bps EBITDA - *468m *1,602m *1,578m -129% -130% -6.8% 17.6% 20.1% Adj PAT¹ - *1,169m Adj EPS1 - 13.0 1. Adj PAT and Adj EPS for Q1 FY22 excludes exceptional items loss of 915m, Biotech and CHC share of loss of 195m, tax credit of *215m on exception items

View entire presentation